Letting the sun shine on patient voices: Perspectives about medications for opioid use disorder in Florida

Sharp, Amanda; Carlson, Melissa; Howell, Veronica; Moore, Kathleen A.; Schuman‐Olivier, Zev

doi:10.1016/j.jsat.2020.108247

Cited by 12 publications

(8 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One main result is that considerations of initiating treatment were guided by iOAT’s perceived positive and negative implications for one’s daily life and individual recovery. Reinforcing the consistency and transferability of our results, this resonates with findings about the initiation of other OAT [15–19] and with health behaviour theory [35].…”

Section: Discussionsupporting

confidence: 91%

“…In addition to the larger structural contexts in which OAT is provided, there is growing interest in perceptions towards treatment as individual-level factors influencing the initiation of OAT [15][16][17][18][19]. These perceptions primarily regard patients' beliefs about a treatment's positive and negative effects and about how perceived attributes of the treatment coincide with individuals' concepts of recovery.…”

Section: The Importance Of Perceptionsmentioning

confidence: 99%

See 1 more Smart Citation

Exploring Patients’ Perceptions on Injectable Opioid Agonist Treatment: Influences on Treatment Initiation and Implications for Practice

Friedmann,

Binder,

Kinkel

et al. 2023

Eur Addict Res

View full text Add to dashboard Cite

Introduction: Injectable opioid agonist treatment (iOAT) with diacetylmorphine is an effective option for individuals previously considered non-responsive to opioid substitution treatment. Despite implementation in Canada and several European countries, relatively few eligible people choose to initiate iOAT. To better understand what encourages or deters prospective patients from initiating iOAT, the current study explores patients’ perceptions on iOAT and how these influence therapy initiation in practice. Methods: We conducted 34 semi-structured interviews with individuals currently in or eligible for iOAT in two German outpatient iOAT clinics. Transcripts were analysed following qualitative content analysis, with development of inductive categories and use of consensual coding. For member checking, we consulted individuals with lived experiences prior to data collection and publication. Results: Participants based their choice to initiate iOAT on the perceived implications of the treatment on one’s daily life and individual recovery. Participants were encouraged to initiate iOAT due to the therapy’s perceived potential in reducing cravings and substance use, its positive health consequences, and due to the image of iOAT as a path towards abstinence. Regarding deterring perceptions, participants feared a profound impairment of daily life due to factors such as the daily visits to the clinic, were concerned about whether iOAT would sufficiently promote or even impede one’s recovery, and described negative health effects. Conclusion: Perceptions found in this study profoundly influenced participants’ decisions on iOAT enrolment and contextualize the previous literature. The study reveals the dynamic coexistence of different perceptions about iOAT and sheds light on the inner-group stigmatization of iOAT. Practitioners and future research should acknowledge the complexities found in the current study in order to exploit the full potential of effective treatment modalities such as iOAT.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: The Importance Of Perceptionsmentioning

confidence: 99%

Exploring Patients’ Perceptions on Injectable Opioid Agonist Treatment: Influences on Treatment Initiation and Implications for Practice

Friedmann,

Binder,

Kinkel

et al. 2023

Eur Addict Res

View full text Add to dashboard Cite

show abstract

“…Alternatively, evidence has found that peer networks significantly influence male AYA substance use treatment decision-making compared to female AYA, 48 reiterating the importance of engaging with peer networks to identify ways to improve MMT retention. [49][50][51][52] Nevertheless, an AYA-specific gender-based analysis on MMT retention may highlight ways to address gender-based gaps in MMT retention among AYA.…”

Section: Discussionmentioning

confidence: 99%

Methadone Maintenance Treatment Discontinuation Among Young People who use Opioids in Vancouver, Canada

et al. 2022

View full text Add to dashboard Cite

Objective Retaining adolescents and young adults (AYA) in medications for opioid use disorder (MOUD), like methadone maintenance treatment (MMT), is critical to reducing toxic drug fatalities. This analysis sought to identify factors associated with MMT discontinuation among AYA. Method Data were derived from the At-Risk Youth Study, a prospective cohort study of street-involved AYA in Vancouver, Canada, between December 2005 and June 2018. Multivariable extended Cox regression identified factors associated with time to MMT discontinuation among AYA who recently initiated MMT. In subanalysis, multivariable extended Cox regression analysis identified factors associated with time to “actionable” MMT discontinuation, which could be addressed through policy changes. Results A total of 308 participants reported recent MMT during the study period. Participants were excluded if they reported MMT in the past 6 months at baseline and were retained in MMT ( n = 94, 30.5%); were missing MMT status data ( n = 43, 14.0%); or completed an MMT taper ( n = 11, 3.6%). Of the remaining 160 participants who initiated MMT over the study period, 102 (63.8%) discontinued MMT accounting for 119 unique discontinuation events. In multivariable extended Cox regression, MMT discontinuation was positively associated with recent weekly crystal methamphetamine use (adjusted hazard ratio [AHR] = 1.67, 95% confidence interval [CI]: 1.19 to 2.35), but negatively associated with age of first “hard” drug use (per year older) (AHR = 0.95, 95% CI: 0.90 to 1.00) and female sex (AHR = 0.66, 95% CI: 0.44 to 0.99). In subanalysis, recent weekly crystal methamphetamine use (AHR = 4.61, 95% CI: 1.78 to 11.9) and weekly heroin or fentanyl use (AHR = 3.37, 95% CI: 1.21 to 9.38) were positively associated with “actionable” MMT discontinuation, while older age (AHR = 0.87, 95% CI: 0.76 to 0.99) was negatively associated. Conclusions Efforts to revise MMT programming; provide access to a range of MOUD, harm reduction, and treatments; and explore coprescribing stimulants to AYA with concurrent stimulant use may improve treatment retention and reduce toxic drug fatalities.

show abstract

“…31 Studies of community-based MOUD have identified avoiding opioid use and improving quality of life as motivating factors and access barriers and desire to be free of any substance use as deterring factors, similar to our study. 20,32 Participants in our study were additionally motivated to begin MOUD before release because they recognized their especially high risk of overdose death after release, and a few participants whose incarceration resulted from drug use hoped that MOUD might help them avoid a return to prison.…”

Section: Discussionmentioning

confidence: 99%

Medications for Opioid use Disorder in State Prisons: Perspectives of Formerly Incarcerated Persons

et al. 2022

View full text Add to dashboard Cite

Background: Opioid use disorder (OUD) is common among incarcerated persons and risk of overdose and other adverse drug-related consequences is high after release. Recognizing their potential to reduce these risks, some correctional systems are expanding access to medication for opioid use disorder (MOUD). This study explored the experiences and perspectives of formerly incarcerated individuals on MOUD use while incarcerated and after release. Methods: We interviewed 53 individuals with self-reported OUD who were released from New Jersey state prisons. Interviews explored motivations to use MOUD while incarcerated and after release, and experiences with prison-based MOUD and transition to community-based care. We performed cross-case analysis to examine common and divergent perspectives across participants. Results: A common reason for accepting prerelease MOUD was recognition of its effectiveness in preventing drug use, overdose, and other drug-related consequences. Participants who chose not to use MOUD often were focused on being completely medication-free or saw themselves as having relatively low-risk of substance use after a prolonged period without opioid use. A few participants reported challenges related to prison-based MOUD, including logistical barriers, stigma, and once-daily buprenorphine dosing. Most participants effectively transitioned to community-based care, but challenges included insurance lapses and difficulty locating providers. Conclusions: Many formerly incarcerated persons with OUD recognize the value of MOUD in supporting recovery, but some hold negative views of MOUD or underestimate the likelihood that they will return to drug use. Patient education on risks of post-release overdose, the role of MOUD in mitigating risk, and MOUD options available to them could increase engagement. Participants’ generally positive experiences with MOUD support the expansion of correctional MOUD programs.

show abstract

Letting the sun shine on patient voices: Perspectives about medications for opioid use disorder in Florida

Cited by 12 publications

References 41 publications

Exploring Patients’ Perceptions on Injectable Opioid Agonist Treatment: Influences on Treatment Initiation and Implications for Practice

Exploring Patients’ Perceptions on Injectable Opioid Agonist Treatment: Influences on Treatment Initiation and Implications for Practice

Methadone Maintenance Treatment Discontinuation Among Young People who use Opioids in Vancouver, Canada

Medications for Opioid use Disorder in State Prisons: Perspectives of Formerly Incarcerated Persons

Contact Info

Product

Resources

About